Blog

Sep 21, 2024, 09:22

Karl Balabanian to visit Armenia for Collaborative Engagements in Immunotherapy and Oncology Research – Immune Oncology Research Institute

Immune Oncology Research Institute shared a post on LinkedIn:

”Great news!

We are excited to share that this October, Dr. Karl Balabanian, Research Director at INSERM and leader of the ‘Chemokines, Lymphoid Niches and Immunopathology’ team at Saint-Louis Hospital and the INSERM U1160 unit, will be visiting Armenia. During his visit, he will engage with the teams at the Immune Oncology Research Institute and the Yeolyan Hematology and Oncology Center.”

Read further.
Source: Immune Oncology Research Institute/LinkedIn

cancer Cancer research Immune Oncology Research Institute Inserm INSERM U1160 unit Karl Balabanian OncoDaily Oncology Saint-Louis Hospital Yeolyan Hematology and Oncology Center

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage